Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy, utilizing its proprietary technology platform to develop advanced cell-based therapies for oncology and degenerative conditions. With a robust pipeline of therapeutics aimed at addressing critical unmet medical needs, Pluri actively forms strategic collaborations that bolster its research and development capabilities. Committed to revolutionizing patient care, Pluri is well-positioned to become a significant contributor in the biotechnology landscape, driving growth and delivering impactful healthcare solutions.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$1.36
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Mar 31, 2026 Report date n/a | $-0.66 | — | — | — | $655.0K | $167.0K | -74.5% | 1D Pre— | On-Day— | 1D Post— |
Q ended Dec 31, 2025 Report date n/a | $-0.65 | — | — | — | $638.0K | $198.0K | -69.0% | 1D Pre— | On-Day— | 1D Post— |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-0.74 | $-0.65 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| Beat +12.2% |
| — |
| $638.0K |
| $316.0K |
| -50.5% |
| 1D Pre+6.2% |
| On-Day+7.5% |
| 1D Post-6.1% |
Q ended Jun 30, 2025 Reported Sep 17, 2025 | $-0.73 | $-1.00 | Miss -37.0% | — | $400.0K | $398.0K | -0.5% | 1D Pre-0.3% | On-Day-3.8% | 1D Post-4.2% |